CTLA-4 +49 A/G and −318 C/T polymorphisms and susceptibility to multiple sclerosis: a meta-analysis

References

• Andreevskii TV, Sudomoina MA, Gusev EI, et al. (2002). [Polymorphism A/G in position +49 of CTLA4 exon 1 in multiple sclerosis in Russians]. Mol Biol (Mosk), 36, 643–8
   PubMed Web of Science ®Google Scholar
• Bagos PG, Karnaouri AC, Nikolopoulos GK, Hamodrakas SJ. (2007). No evidence for association of CTLA-4 gene polymorphisms with the risk of developing multiple sclerosis: a meta-analysis. Mult Scler, 13, 156–68. doi: 10.1177/1352458507078059
   PubMed Web of Science ®Google Scholar
• Bilinska M, Frydecka I, Noga L, et al. (2004). Progression of multiple sclerosis is associated with exon 1 CTLA-4 gene polymorphism. Acta Neurol Scand, 110, 67–71. doi: 10.1111/j.1600-0404.2004.00271.x
   PubMed Web of Science ®Google Scholar
• Bocko D, Bilinska M, Dobosz T, et al. (2003). Lack of association between an exon 1 CTLA-4 gene polymorphism A(49)G and multiple sclerosis in a Polish population of the Lower Silesia region. Arch Immunol Ther Exp (Warsz), 51, 201–5
   Google Scholar
• Borhani Haghighi A, Ghahramani S, Azarpira N, et al. (2008). Cytotoxic T lymphocyte associated antigen-4 exon 1 A/G polymorphism in Iranian patients with multiple sclerosis. Eur J Neurol, 15, 862–4
   PubMed Web of Science ®Google Scholar
• Cizmarevic NS, Gasparovic I, Peterlin B, et al. (2011). CTLA-4 +49 A/G gene polymorphism in Croatian and Slovenian multiple sclerosis patients. Int J Immunogenet, 38, 419–26. doi: 10.1111/j.1744-313X.2011.01027.x
   PubMed Web of Science ®Google Scholar
• DerSimonian R, Laird N. (1986). Meta-analysis in clinical trials. Control Clin Trials, 7, 177–88. doi: 0197-2456(86)90046-2 [pii]
   PubMed Web of Science ®Google Scholar
• Dincic E, Zivkovic M, Stankovic A, et al. (2006). Association of polymorphisms in CTLA-4, IL-1ra and IL-1beta genes with multiple sclerosis in Serbian population. J Neuroimmunol, 177, 146–50. doi: 10.1016/j.jneuroim.2006.05.005
   PubMed Web of Science ®Google Scholar
• Egger M, Davey Smith G, Schneider M, Minder C. (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ, 315, 629–34
   PubMed Web of Science ®Google Scholar
• Fukazawa T, Kikuchi S, Miyagishi R, et al. (2005). CTLA-4 gene polymorphism is not associated with conventional multiple sclerosis in Japanese. J Neuroimmunol, 159, 225–9. doi: 10.1016/j.jneuroim.2004.10.012
   PubMed Web of Science ®Google Scholar
• Fukazawa T, Yanagawa T, Kikuchi S, et al. (1999). CTLA-4 gene polymorphism may modulate disease in Japanese multiple sclerosis patients. J Neurol Sci, 171, 49–55
   PubMed Web of Science ®Google Scholar
• Gibson AW, Li FJ, Wu J, et al. (2009). The FCRL3-169CT promoter single-nucleotide polymorphism, which is associated with systemic lupus erythematosus in a Japanese population, predicts expression of receptor protein on CD19+ B cells. Arthritis Rheum, 60, 3510–2. doi: 10.1002/art.24915
   PubMedGoogle Scholar
• Greenwald RJ, Oosterwegel MA, van der Woude D, et al. (2002). CTLA-4 regulates cell cycle progression during a primary immune response. Eur J Immunol, 32, 366–73. doi: 10.1002/1521-4141(200202)32:2<366::AID-IMMU366>3.0.CO;2-5 [pii] 10.1002/1521-4141(200202)32:2&#60;366::AID-IMMU366&#62;3.0.CO;2-5
   PubMed Web of Science ®Google Scholar
• Greve B, Simonenko R, Illes Z, et al. (2008). Multiple sclerosis and the CTLA4 autoimmunity polymorphism CT60: no association in patients from Germany, Hungary and Poland. Mult Scler, 14, 153–8. doi: 10.1177/1352458507082357
   PubMed Web of Science ®Google Scholar
• Gribben JG, Freeman GJ, Boussiotis VA, et al. (1995). CTLA4 mediates antigen-specific apoptosis of human T cells. Proc Natl Acad Sci USA, 92, 811–5
   PubMed Web of Science ®Google Scholar
• Habek M, Brinar VV, Borovecki F. (2010). Genes associated with multiple sclerosis: 15 and counting. Expert Rev Mol Diagn, 10, 857–61. doi: 10.1586/erm.10.77
   PubMed Web of Science ®Google Scholar
• Han S, Li Y, Mao Y, Xie Y. (2005). Meta-analysis of the association of CTLA-4 exon-1 +49A/G polymorphism with rheumatoid arthritis. Hum Genet, 118, 123–32. doi: 10.1007/s00439-005-0033-9
   PubMed Web of Science ®Google Scholar
• Harbo HF, Celius EG, Vartdal F, Spurkland A. (1999). CTLA4 promoter and exon 1 dimorphisms in multiple sclerosis. Tissue Antigens, 53, 106–10
   PubMedGoogle Scholar
• Heggarty S, Suppiah V, Silversides J, et al. (2007). CTLA4 gene polymorphisms and multiple sclerosis in Northern Ireland. J Neuroimmunol, 187, 187–91. doi: 10.1016/j.jneuroim.2007.04.017
   PubMed Web of Science ®Google Scholar
• Heidari A, Noori Daloii MR, Keramatipour M, et al. (2010). CTLA-4 gene polymorphisms (-318C/T, +49A/G, +6230A/G) in Iranian patients with multiple sclerosis. Iran J Allergy Asthma Immunol, 9, 219–23. doi: 09.04/ijaai.219223
   PubMed Web of Science ®Google Scholar
• Higgins JP, Thompson SG. (2002). Quantifying heterogeneity in a meta-analysis. Stat Med, 21, 1539–58. doi: 10.1002/sim.1186
   PubMed Web of Science ®Google Scholar
• Kantarci OH, Hebrink DD, Achenbach SJ, et al. (2003). CTLA4 is associated with susceptibility to multiple sclerosis. J Neuroimmunol, 134, 133–41
   PubMed Web of Science ®Google Scholar
• Karabon L, Kosmaczewska A, Bilinska M, et al. (2009). The CTLA-4 gene polymorphisms are associated with CTLA-4 protein expression levels in multiple sclerosis patients and with susceptibility to disease. Immunology, 128, e787–96. doi: 10.1111/j.1365-2567.2009.03083.x
   PubMed Web of Science ®Google Scholar
• Lee YH, Harley JB, Nath SK. (2005). CTLA-4 polymorphisms and systemic lupus erythematosus (SLE): a meta-analysis. Hum Genet, 116, 361–7. doi: 10.1007/s00439-004-1244-1
   PubMed Web of Science ®Google Scholar
• Lee YH, Rho YH, Choi SJ, et al. (2006). Association of TNF-alpha -308 G/A polymorphism with responsiveness to TNF-alpha-blockers in rheumatoid arthritis: a meta-analysis. Rheumatol Int, 27, 157–61. doi: 10.1007/s00296-006-0175-7
   PubMed Web of Science ®Google Scholar
• Lee YH, Witte T, Momot T, et al. (2005). The mannose-binding lectin gene polymorphisms and systemic lupus erythematosus: two case-control studies and a meta-analysis. Arthritis Rheum, 52, 3966–74. doi: 10.1002/art.21484
   PubMed Web of Science ®Google Scholar
• Ligers A, Xu C, Saarinen S, et al. (1999). The CTLA-4 gene is associated with multiple sclerosis. J Neuroimmunol, 97, 182–90
   PubMed Web of Science ®Google Scholar
• Lorentzen AR, Celius EG, Ekstrom PO, et al. (2005). Lack of association with the CD28/CTLA4/ICOS gene region among Norwegian multiple sclerosis patients. J Neuroimmunol, 166, 197–201. doi: 10.1016/j.jneuroim.2005.06.002
   PubMed Web of Science ®Google Scholar
• Luomala M, Lehtimaki T, Huhtala H, et al. (2003). Promoter polymorphism of IL-10 and severity of multiple sclerosis. Acta Neurol Scand, 108, 396–400
   PubMed Web of Science ®Google Scholar
• Malferrari G, Stella A, Monferini E, et al. (2005). Ctla4 and multiple sclerosis in the Italian population. Exp Mol Pathol, 78, 55–7. doi: 10.1016/j.yexmp.2004.10.001
   PubMed Web of Science ®Google Scholar
• Masterman T, Ligers A, Zhang Z, et al. (2002). CTLA4 dimorphisms and the multiple sclerosis phenotype. J Neuroimmunol, 131, 208–12
   PubMed Web of Science ®Google Scholar
• Maurer M, Ponath A, Kruse N, Rieckmann P. (2002). CTLA4 exon 1 dimorphism is associated with primary progressive multiple sclerosis. J Neuroimmunol, 131, 213–5
   PubMed Web of Science ®Google Scholar
• Nath SK, Harley JB, Lee YH. (2005). Polymorphisms of complement receptor 1 and interleukin-10 genes and systemic lupus erythematosus: a meta-analysis. Hum Genet, 118, 225–34. doi: 10.1007/s00439-005-0044-6
   PubMed Web of Science ®Google Scholar
• Rasmussen HB, Kelly MA, Francis DA, Clausen J. (2001). CTLA4 in multiple sclerosis. Lack of genetic association in a European Caucasian population but evidence of interaction with HLA-DR2 among Shanghai Chinese. J Neurol Sci, 184, 143–7
   PubMed Web of Science ®Google Scholar
• Teutsch SM, Booth DR, Bennetts BH, et al. (2004). Association of common T cell activation gene polymorphisms with multiple sclerosis in Australian patients. J Neuroimmunol, 148, 218–30. doi: 10.1016/j.jneuroim.2003.12.003
   PubMed Web of Science ®Google Scholar
• Ueda H, Howson JM, Esposito L, et al. (2003). Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature, 423, 506–11. doi: 10.1038/nature01621 nature01621 [pii]
   PubMed Web of Science ®Google Scholar
• van Veen T, Crusius JB, van Winsen L, et al. (2003). CTLA-4 and CD28 gene polymorphisms in susceptibility, clinical course and progression of multiple sclerosis. J Neuroimmunol, 140, 188–93
   PubMed Web of Science ®Google Scholar
• Wang XB, Zhao X, Giscombe R, Lefvert AK. (2002). A CTLA-4 gene polymorphism at position -318 in the promoter region affects the expression of protein. Genes Immun, 3, 233–4. doi: 10.1038/sj.gene.6363869
   PubMed Web of Science ®Google Scholar
• Wray BN, Stankovich J, Whittock L, et al. (2008). CTLA-4 and multiple sclerosis: the A49G single nucleotide polymorphism shows no association with multiple sclerosis in a Southern Australian population. J Neuroimmunol, 196, 139–42. doi: 10.1016/j.jneuroim.2008.02.001
   PubMed Web of Science ®Google Scholar
• Yousefipour G, Erfani N, Momtahan M, et al. (2009). CTLA4 exon 1 and promoter polymorphisms in patients with multiple sclerosis. Acta Neurol Scand, 120, 424–9. doi: 10.1111/j.1600-0404.2009.01177.x
   PubMed Web of Science ®Google Scholar